http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

Shares in issue: 147.4m 1p Ords

Major Shareholders Amount % Holding

John Dawson 46,685,079 31.68
Stella Anne Dawson 15,576,323 10.57
RAB Capital PLC 8.80
Chase Nominees Limited 9,164,675 6.22
Aviva PLC 6.00
F&C Asset Management PLC 4.90
Anthony Richard Booley 6,710,723 4.55
Fidelity Management & Research Company 6,500,000 4.41
Artemis Inv Mgmt Ltd 4.10

Nigel Wray 5,655,407 3.84

Morstan Nominees Ltd 5,532,399 3.75

-------------------------------------

Alliance Pharma says Nigel Wray buys shares

LONDON (AFX) - Alliance Pharma PLC said Nigel Wray has acquired 3,500,000
ordinary shares in the company, representing 2.38 pct and now holds 5,655,407
shares, representing 3.84 pct.

newsdesk@afxnews.com slm/ Nov 2004

Always keep an eye on what NW buys into..........

Alliance Pharma PLC
28 February 2005

For immediate release: 28th February 2005





ALLIANCE PHARMA PLC

('Alliance' or 'the Company')

DIRECTOR'S SHARE DEALING



On 22nd February 2005, Paul Ransom, a non-executive Director of Alliance Pharma
plc, purchased 48,000 shares at 15.5p. The purchase represents the total amount
of his holding in the Company.



- ends -





For further information please contacts:



Alliance Pharma plc
John Dawson, CEO
01249 466966



Beattie Financial
Mike Wort/John Moriarty
020 7398 3300




This information is provided by RNS
The company news service from the London Stock Exchange

Take a read of this

"http://miranda.hemscott.com/ir/aph/docs/InstitutionsPresentation.ppt#256,1,Alliance Pharma plc Project Byron"

PapalPower: Thanks - apppreciated yout posting - my kind of recovery stock. RAB involvement jumped out
at me - shrewd guys those.
sd.

Glad I'm just watching. Down over 6% today on a 100k sell.
But my gambler's instinct tells me it's near the bottom where we bottom fishers love to feed.
sd.

Welcome squidd, add into it that Nigel Wray is there too, something is happening - even more so by the complete quiet being kept around it at the moment.

Prelim is expected around the 12th May, have to watch for any large buys going on April onwards.

squidd, if you like being a bottom feeder, take a look at OSH, its a high risk, potential high reward one, however, its a recession free industry and one which will continue to grow. The previous CEO messed up a bit and the price got hammered, new CEO was in a month before the last results and I am expecting improved profits, restructuring done and a very positive outlook come reporting time. If you like RAB and their investments, take a look at the shareholders for TAG, expect things to move on that one around June time.

Good news today.

Alliance Pharma PLC
16 March 2005

For immediate release: 16th March 2005



ALLIANCE PHARMA PLC
('Alliance' or 'the Company')


PRE-CLOSE TRADING UPDATE


Alliance Pharma plc, the emerging speciality pharmaceutical company, is pleased
to provide a trading update prior to entering its closed period for the full
year to 28 February 2005.


Profits are anticipated to be within the range of analysts' expectations. Sales
for the year ending 28 February 2005 are expected to be in the region of 11.8
million, up from 10.4 million last year.


Trading performance is showing sales growth of 13%, over the same period in the
previous financial year. Growth on a like-for-like basis was 7%, with a further
6% growth being achieved through acquisitions.


The company made two acquisitions in November 2004: Forceval, a prescription
multivitamin and mineral supplement that is licensed and reimbursed on the NHS
in the UK and sold to various other overseas markets via distributors, and
Periostat, a pharmaceutical treatment for periodontitis, for the UK and all the
other countries in the European Union as well as Switzerland, Israel, South
Africa, Australia and New Zealand.


In the four months since the acquisitions of Forceval and Periostat, the Company
is pleased to announce that sales of both products have been in line with
expectations. Since acquisition, Alliance Pharma has strengthened the
relationships with the international distributors and the order book for
international sales going forward is in line with its expectations. To drive
Forceval's international expansion, the Company is looking forward to announcing
the appointment of a Head of the International Division within the next few
weeks. Similarly, to start to unlock the potential within Periostat, the
appointment of the Head of the Dental Division will be announced shortly


The registration trial programme for Alliance's development drug, misoprostol
for the induction of labour (APL202), which commenced in January, is continuing
according to plan. Approvals are expected soon to permit the trials programme
for Melatonin for sleep disorders (APL 510) to commence.


John Dawson, CEO of Alliance Pharma, commented:


'2004 has been another important year for Alliance. We have continued our
growth and further strengthened our portfolio. Periostat, in particular, has
tremendous growth potential. Good progress has also been made on our
development projects, adding greatly to our mid-term prospects'.


Preliminary results for the 12 month period to 28 February 2005 will be
announced on Thursday 12th May 2005.


- ends -


For further information:



Alliance Pharma plc
John Dawson, CEO
01249 466966


Beattie Financial
John Moriarty
020 7398 3300






This information is provided by RNS
The company news service from the London Stock Exchange

Periostat (mentioned in the trading statement) is one that is going to really boost the P+L account mid term.


Enzyme suppressor as a novel adjunctive therapy for serious gum disease (periodontitis)
Developed by CollaGenex (US)
Sales currently 347k (281k UK)
High growth potential UK sales currently based on 6,000 patients from pool of 3.2m
US sales $45m after 5 yrs
Alliance has agreed contract for EU, Switzerland, Israel, Australia, NZ and S. Africa

As RAB Capital is into APH


Friday 18th March LONDON - Hedge fund manager Rab Capital saw a 65% rise in pre-tax profit and a 75% increase assets under management last year with another surge in January and February of this year.

Pre-tax profit was 17.5m compared with 10.6m last time, a 13-month period to December 2003.

Assets under management by Rab rose to $1.75bn compared to $1.02bn previously, but are now believed to be through the $2bn barrier following a 25% rise in the past two months.

"Performance for the first two months of 2005 has significantly exceeded the same period of 2004 and assets under management have grown strongly since the year end," said the company.

Sales revenue of 36.2m came in 56% higher than 2003. Management fees went up from 6.6m in 2003 to 10.1m in 2004.

The dividend for the year doubles to 0.50p from 0.25p in 2003.

PpP: Having looked at APH, I feel no urge to climb aboard at present. It has a bland website, miniscule director buys, low traded volumes and no sign yet of recovery on the charts. TED looks much more promising on all these counts and have recently bought them. However, with the heavyweight institutional support for APH that you point out, they are now on my watch list.
OSH came up on my radar with modest director buys, but so far they seem to be stuck in a downtrend; and I can't find a proper website for them, only something about dentistry, so will contine to watch.
sd.

squidd : At present it appears nothing exciting at APH short term, I shall be looking for any more institutional support that comes in short term, and then the news on results. APH looks attractive presently in the mid term, but as we all know, anything can happen, I would not expect any short term downside or bad news - so even holding in the short term "can" only give upside on good news.

OSH web site is www.oasis-healthcare.com. This is a recovery play. High turnover and high debt (debt is due to building the group) - the debt is "not" a worry IMO owing to the business plan. If the results are good, this will rebound strongly. The new man in charge, Stephen Lambert, in for a year now, should have turned it around - so potential large bounce on the results. OSH are trying to do the same with dentistry as Boots and the like did with pharmacy - take a fragmented market and turn it into a large group. Its a growing market and recession proof. Just need to wait and see if Lambert has made the changes needed, after the last man messed up a bit. IMO, turn around will be stated soon.

PpP: Wakened by the sweet sound of much needed rain. Thanks for updated info on APH and OSH; both high on my watch list.
Have you looked at my earlier pharma recovery stocks - TED and post-crash ELA.
sQd.

Alliance Pharma PLC
30 March 2005

For immediate release: 30 March 2005





ALLIANCE PHARMA PLC

('Alliance' or 'the Company')


SHAREHOLDINGS IN COMPANY



Fidelity acquire an additional 3,700,000 ordinary shares





On 30th March 2005 the Company was notified by Fidelity Investments, ('FMR Corp
'), that it had increased its shareholding by 3,700,000 shares. The notifiable
interest is with FMR Corp and Fidelity International Limited (FIL) which also
comprises the notifiable interest of Mr Edward C Johnson 3d, a principal
shareholder of FMR Corp and Fidelity International Limited. The shares held
currently are as follows:


Shares Held Management Company Nominee/Registered Name
240,500 FIL Brown Brothers Harriman Ltd LUX
9,959,500 FMRCO Mellon Bank
TOTAL 10,200,000



The total percentage shareholding of FMR Corp and Fidelity International Limited
is now 9.43%

Prelims est 12th May.

We have a buyer it seems, looking at trade values and timings.

16:38:44 13-Apr-2005 13.00 50,000 6,500.00 Single protected transaction
16:38:44 14-Apr-2005 13.00 50,000 6,500.00 Single protected transaction

Same time to the second.

Another 50K today at 16:38 and 44 seconds ?

13M Cross Trade today (9% of all shares)

Alliance Pharma PLC
09 May 2005


For immediate release 9 May 2005

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Announces Co-Promotion Agreement with OralDent Ltd

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce a co-promotion agreement with OralDent Ltd ('OralDent'),
a privately owned dental products company, for the UK marketing and distribution of Periostat(R), a prescription medicine for the treatment of the severe gum disease periodontitis.

Periostat is a major growth opportunity for Alliance Pharma and this agreement
with OralDent marks the first step in the roll-out of the product across the
territories for which the Company holds marketing rights. Alliance Pharma
acquired the rights in November 2004 from CollaGenex International Ltd, part of
CollaGenex Pharmaceuticals Inc (Nasdaq: CGPI), for the territories of the
enlarged European Union, Switzerland, Israel, Australia, New Zealand and South
Africa.

The international roll-out of the product will be led by a senior international
manager, who was recently appointed to head the Company's newly formed
International Division.

OralDent focuses on promoting products to private and NHS dentists in the UK via a field sales force, a tele-sales operation and an internet portal. Alliance Pharma will contribute resources to enable OralDent to increase the size of its sales force to maximise the sales of Periostat. Alliance Pharma will recognise the Periostat sales and OralDent will receive sales-based royalties on a sliding scale between 5%per cent and 15% per cent.

Periostat is the first and only approved oral pharmaceutical product for the
adjunctive treatment of adult periodontal disease (periodontitis) by the
suppression of those enzymes that destroy periodontal support tissues. Periostat is included in the Secretary of State for Health's list for dental prescribing and is listed on the UK's Dental Practitioners' Formulary. Periodontitis is estimated to affect 11 per cent of the adult population in the UK.

Commenting, John Dawson, Alliance Pharma's Chief Executive, said: 'Periostat is
a major growth opportunity for the Company and this UK co-promotion agreement is an important first step in maximising the potential of the product. OralDent has a particularly strong franchise in the UK dental market and we look forward to a successful collaboration with them.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

And some strong buying yesterday.

PpP: I see our favourite pharma's continue to storm uphill and thanks to a takeover rumour today, ELA takes the lead. Nice to see some splashes of blue inside, with the bluebells outside.
sd.

Read this today squidd

One top market analyst turns bullish on the undervalued shares of major pharmaceutical companies.

NEW YORK May 10th 2005 - Among the important market analysts I follow, Steve Leuthold is one of the best. His Leuthold Group does extensive historical analysis of the stock and bond markets chiefly for institutional investors.
The firm maintains a managed model stock portfolio that is conservative and value-oriented. Moreover, the portfolio mix changes only slightly from month to month. So when Leuthold makes a major move, it's worth taking seriously.
As of May, the Leuthold Group has added the major pharmaceuticals group to its model portfolio. The big drug stocks were last rated Attractive by the firm in June 2003.
The firm's analysts have been intrigued by the beatings that big pharmaceutical companies took during the past several months, says Leuthold, and were waiting for this down and out group to reach attractive valuation levels again.
The big drug stocks currently trade at price/earnings ratios of 14 to 21, based on estimated 2005 earnings, and yield from 2 percent to 4.4 percent. By comparison, the average blue chip now trades at a 17 P/E, and the S&P 500 yields only 1.9 percent.
This portfolio adjustment is just the latest increase in the Leuthold Group's broader commitment to health care. The firm's core portfolio now has a 26 percent allocation to health care, while that sector accounts for less than 14 percent of the S&P 500's market cap.

More good news squidd

Alliance Pharma PLC
11 May 2005


For Immediate Release 11 May 2005




Alliance Pharma Plc

Notification of Major Interests in Shares

Nigel Wray acquires additional shares in Alliance Pharma



On 5 May 2005, the company was notified by Nigel Wray that he has purchased an
additional 700,000 shares in the company bringing his total holdings in Alliance
Pharma to 6,355,407 ordinary shares or 4.31% of the issued share capital.


-ENDS-

PpP: Thanks for this. Obviously, Nigel doesn't share my concerns about the big picture and this is highly encouraging. I'm clearing out some dogs from my portfolio at present and will look again in a few days.
sd.

Squidd here we go.


Alliance Pharma PLC
12 May 2005
For Immediate Release 12 May 2005

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Preliminary Results for the year ended 28 February 2005



Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its preliminary results for the year ended 28 February
2005. These are the Company's first full year results as a listed company,
following the Company's admission to AIM in December 2003.

Financial Highlights


Turnover increased 13% to 11.8 million (2004: 10.4m) - the full year
impact of two product acquisitions in November 2004, Periostat(R) and
Forceval(R), would show an annualised turnover of 15m

Gross margin improved to 52.4% (2004: 48.4%)

Adjusted EBAT (earnings before exceptional items, amortisation and
tax) of 0.645 million (2004: 1.21m) - the decrease largely reflecting the
investment in infrastructure and the marketing expenditure associated with
current and pipeline products

Profit before tax of 0.418 million (2004: loss of 2.15m)

Operating cashflow remains strong at 1.59 million (2004: 2.11m)

Adjusted earnings per share 0.52p (2004: 1.18p)

Basic earnings per share 0.34p (2004: loss per share of 2.44p)


Operational Highlights

Continued strong sales growth of Symmetrel(R)and Nu-Seals(R)

Acquisition of Periostat and Forceval in November 2004

Regulatory approval anticipated imminently to begin clinical trials of
Posidorm(TM), melatonin in sleep disorders

Start of Phase III clinical trials in January 2005 of APL 202
misoprostol for the induction of labour

Launch of International division to drive overseas sales through
out-licensing and distributors

Co-promotion agreement signed with OralDent Ltd for the UK marketing
and distribution of Periostat(R), a prescription medicine for the treatment
of the severe gum disease periodontitis


Commenting on the results, John Dawson, Alliance Pharma's Chief Executive, said:
'These results underline the robustness of Alliance Pharma's business model, in
which the cashflow from our marketed products supports the development of our
clinical pipeline. We will shortly commence the trial programme leading to
registration for our product Posidorm(TM) for sleep disorders, which seeks to
address a market that is currently at 0.5bn but which is expected to treble in
the next decade.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

squidd another potential one to add to the recovery pipeline is Kuju (KUJ) who have done their changes some time ago and with some excellent recent contract news which should grow with E3 not far away. They also I hope should be returning to profits in the results due not so far in the future with their new set up and working method allowing profitable growth and a confident outlook statement.

Been noticing that some shorters are working on some sites to slag off companies like OSH APH VLK this is a good sign as they are trying it on with the general weakness hoping to bring the price down so they can then go long over the summer and autumn. Hitting the shares that are already priced down on previous old bad news is easy and often they post no facts or just old news but I think they might fail as people can see the return well underway to better times ahead.

ELA still looking good.

Have you looked at UNG ? its been hit and things are very positive for the future and the price to book value is well under 1

squidd there is more good news here too as well as UNG;

Alliance Pharma PLC
16 May 2005
For Immediate Release 16 May 2005



ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Director's Share Dealing

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce that Michael Gatenby, Chairman of Alliance Pharma plc,
purchased 50,000 shares at 14.45p, bringing his total in the company to 130,000
shares which represents 0.088% of the total issued share capital.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

PpP: A bottom fisher's dream. Fall off cliff - 4 years floundering in the depths - solid looking base at all time low - director's buy. Precisely my kind of share.
Thanks also for exciting news on ICN and on UNG. Took fright when I first read the latter, I thought it said 'buy stanelco', but with the right glasses on it said 'buy' stance.
Noticed the splashes of blue on the PpP portfolio today. Keep it up.
sd.

squidd a little more news on APH. I think the shorters in VLK have now gone as well as from APH by the looks of the sells on the way up but I think someone still trying to short OSH down further but the buys yesterday might firm it up as its so cheap already with news in June its going to get more buyers.


Alliance Pharma PLC
17 May 2005

Alliance Pharma Plc

Notification of Major Interests in Shares

On 11 May 2005, the company was notified by RAB Capital that they have an
interest in 13,018,399 shares of the company, representing 8.83% of the issued
share capital.

RAB Capital does not act as custodian for its clients and therefore the shares
are held in the nominee name of the custodian of its clients, which are CSFB
Nominees Ltd and Morgan Stanley & Co. International Ltd.

-ENDS-

PpP: Have followed ch M.G. Tues am and bought 50K at the same price 14.45, getting inside the spread with comdirect in time to catch the pm rise. Funded this with sale of ORCA, an impulse buy earlier in the year and one of few non-recovery stocks in my portfolio, all of which leaves my cash pile intact. All looking good with APH, particularly the OBV, not that I take too much notice of it, but it seems to impress my TA friends.
Added PCM to my watch list last week, and this enjoyed staggering volumes yesterday - perhaps another asian tiger awaking?
And the PpP portfolio continues upwards.
sd.

squidd will take a look at PCM I am hoping for more good things from APH maybe another director buy maybe and I think the shorter left yesterday by the large sells on the rise which should mean its able to go up more freely now. Some good news flow from KUJ this week although I know its not one to excite you.

squidd PCM looks very interesting and heavy volumes. I have just put a thread in for HML as they got a write up today as speculative buy and well bottomed at the moment, all is good on the APH front.

squidd here is the Hardman May update;

From Hardmans monthly review for May 2005;

ALLIANCE PHARMA
Alliance Pharma announced its full year results on 12th May. There were few surprises following the preclose update given just over a month ago. Prior to the release of the results Alliance had confirmed that
it has signed a deal with OralDent Ltd, a privately owned dental products company, to co-promote Alliances Periostat treatemnt for the gum
disease periodontitis. In October last year Alliance acquired the marketing rights for Periostat in the EU, Australia, South Africa and New Zealand from the US group CollaGenex Inc,for a total cost of 1.85m.
Periostat is not protected by patents in the UK and Europe but a data exclusivity agreement provides protection against generic competition until
2010. Under the new deal Oraldent will promote Periostat to UK dentists via a field sales force, a telesales operation and an internet portal. Alliance will
recognise these sales and pay Oraldent sales-based royalties on a sliding scale between 5% and 15%.
At present Periostat is only prescribed in the UK to 6000 patients (0.2% of the potential prescribing opportunities). Given a focused marketing
campaign there is clearly scope to grow this amount. It is noteworthy that in the US sales of Periostat have almost tripled to around $45m a year since 1999.
In a separate development Alliance last month appointed Glynys Davies to head the companys new Dental Products Division (which will promote
Periostat and other products). Glynys Davies has held senior marketing positions with the leading dental product company Dentsply and dental
implants specialist 3i Implant Innovations.
Alliance has also appointed Alexander Scholtens Weert head of the companys new International Division. Mr Scholtens Weert has held marketing positions at Eli Lilly and Roche and was marketing director of Europe, Africa and the Middle East at the medical devices company MinMed. Alliances new International
Division will promote overseas sales of Periostat and Forceval.

Some buyers returning today squidd might mean some news soon.

PpP: Thanks for APH newsflow. Is there a dental bias in your outlook?
ELA is back on track, with some catching up to do, but I remain hopeful. Had a look at CCN again, it used to be on my recovery watchlist from the ASOS challenge days, but I think I was right to delete it; purely from the chart point of view it doesn't for me hold the recovery attractions of ULT or PCM. The latter also has dentistry products.
sd.

squidd another move up today for APH. I am getting excited about Wednesday with OSH results and am hoping for news that the restructuring is all but finished and now very positive looking forward with more profit and more money available to grow the business.
News on the dental drug Periostat would be good for APH as this is going to be a massive revenue earner for APH but any other trial type news would be good or Nigel Wray buying more and more. Dental things to me seems good as it does not matter what the price of oil is and its a growing business.

PpP: Nice to see the blue ink around the portfolio. My front runner is now CSB, I'm adding to this and also ULT and PCM.
sd.

squidd nice to see the buying continue on APH and a good 100K buy at the end of yesterday.

PpP: My chartist friend tells me that the recent 25 - 65 MA cross on APH is a significant event that may point to an upward breakout. It coincides with your encouraging news, so here's hoping.
sd.

squidd it looks like another up day today !!

squidd here is why;

http://www.timesonline.co.uk/printFriendly/0,,1-5-1661099,00.html

June 20, 2005

Biotech sees riches in sleeping market
By Richard Irving

A DRUG that could end the nightmare of long-term sleep deprivation is about to enter phase three trials.

Posidorm will begin final testing among 600 volunteers across Britain next month and, if successful, could unlock a market that is estimated to be worth 4 billion (2.7 billion) a year from 2007 for the Chippenham-based biotech Alliance Pharmaceuticals. It is estimated that about 20 million people in Europe, including the elderly, shift-workers and the blind, suffer some form of long-term sleep deprivation.

Regulatory approval might also help the medicine to achieve cult status as a lifestyle treatment among travellers suffering jetlag and even among late-night revellers.

Posidorm is a synthetic replica of melatonin, a hormone produced in the pineal gland at the back of the eye. The body ramps up production of the chemical as darkness falls to help to induce drowsiness. Production stops around dawn.

The hormone is available in the United States as a dietary supplement, but regulators elsewhere believe that the treatment should be developed as a pharmaceutical so that it can be properly clinically tested.

It is unlikely that Alliance will be able to protect Posidorm with patents, although the company will file for regulatory approval under the orphan drug programme, which will give it exclusive marketing rights for ten years.

John Dawson, the Alliance founder, who with his wife owns 42 per cent of the business, plans to seek a licensing partner to help to sell the medicine.

The sleep disorder market is almost completely unsatisfied, he said. If we can capture just 1 per cent of the potential for this treatment in Europe, we can bring in 40 million of sales a year.

Doctors struggle to treat insomnia. They are reluctant to prescribe sedatives, partly because they are addictive and can be abused in large doses and partly because they lose their efficacy over time.

Posidorm will be formulated in a tablet so that patients get an initial, fast-acting dose to help to bring on sleep and a subsequent top-up that releases slowly throughout the rest of the night.

Alliance was founded in 1996 to exploit mature drug brands that big pharma no longer considered profitable. It struck its first deal in 1998, when it picked up 16 brands under a marketing and distribution deal with Novartis. It floated on AIM in 2003 and last year made two significant brand acquisitions: Periostat, a treatment for gum disease, and Forceval, a prescription drug containing 24 vitamins and minerals for use among people who are malnourished.

Alliance reported a pre-tax profit of 400,000 in the year to the end of February on sales of 11.8 million.

PCF Last week issues an RNS stating that they had been approached in the early stages of a bid. The current valuation is way to low and is about to rocket with the full bid any day. The company is moving back into profit and several broker/tipster recommended it as a buy prior to the bid news

On top of this there is a rumour of a second bidder in the wings going about

This will reach new highs this week, now is the time to get in before it heads toward 100p, current sp is 32p

IMHO

squidd more info;

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

PpP: (I presume trader4 is a crossed thread)
The APH chart is looking more and more like a classic recovery play, backed up by your excellent news flow. I was pleasantly surprised to learn about Posidorm, having not noted it earlier, so I'm glad to be on board.
I am now looking hard at TAG.
sd.

squidd more good news;

RNS Number:8284N
Alliance Pharma PLC
21 June 2005
For Immediate Release

ALLIANCE PHARMA PLC
Annual General Meeting Statement

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
held its Annual General Meeting in London today, at which all resolutions were
duly passed.

At the meeting, Michael Gatenby, Alliance Pharma's Chairman, said:

"The first quarter has seen a continuation of the progress reported at our full
year results. Sales have continued to grow, and are on target to meet
expectations. At the full year we highlighted our improving gross margin, and I am pleased to report that first quarter trading has continued to reflect this
trend.

"Good progress continues to be made with our development projects: Posidorm
(melatonin) for sleep disorders and Isprelor (misoprostol) for induction of
labour.

"In addition, and in line with our strategy, we will continue to seek high
quality, cash generative acquisitions of established prescription brands."

At the Extraordinary General Meeting later the same day the Company Share Option Scheme was approved.
ENDS
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

squidd another big vote of confidence;

Alliance Pharma PLC
24 June 2005
For Immediate Release 24 June 2005

Alliance Pharma Plc

Notification of Major Interests in Shares

Nigel Wray acquires additional shares in Alliance Pharma

On 23 June 2005, the company was notified by Nigel Wray that he has purchased
an additional 3,250,000 shares at 15p in the company bringing his total holdings in Alliance Pharma to 9,605,407 ordinary shares or 6.58% of the issued share capital.

-ENDS-

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

squidd we should get some more news soon as well as on Wednesday 22nd in the last 30 minutes of trading there was over 19 million buys at 15p, so now we know 3.25 million was Nigel Wray but whose were the others ?

squidd a good rise today and we should have more news coming next week on who purchased the other 16 million at the same time as Nigel Wray.

PpP: On a day when the market as a whole was depressed, it was a particularly good performsnce by APH. My chart now seems to be looking up at the sky.
I've been looking into the history of Nigel Wray's investment history. He certainly had a mixed record as an entreprenuer during the dotcom boom years, like the rest of us, but latterly seems to have matured and made many shrewd moves. He obviously bears watching as APH (and others) progress.
sd.

squidd all is looking good and in terms of increased growth Periostat will give this however should the other ones come on line after phase 3 trials then it will keep pointing at the sky. The mid term for APH is very strong and of course they are already a profit making company.

I have the very same feelings on OSH and shall be adding in the coming weeks and months, OSH for me is short term small ups (maybe some small downs) but then it will go skyward mid term.

squidd another blue start to the day and poiting very much to the sky.

PpP: Yes! Nothing like a splash of blue at the top of the alphabet to beat the Monday morning blues. (But shouldn't say that as a holder of ULT).
Your new thread header on it's own, is worth a couple of points and APH, in the short time I've held it is challenging my front runner CSB.
I continue to look hard at TAG but not finding anything new.
sd.

squidd the two big delayed reporting buys early in the morning (shown as 150K sells as reported after the move up) is what pushed it up, followed by a 25K sell at mid price. Very short of stock here and any large buy is pushing it up more and we are still due more news on holdings increases in my opinion this week.

squidd the MM's must be very short of stock as its gone up again after a little bit more buying.

squidd its another lovely blue day and looking strong for the rest of the week.

Melatonin is starting to appear on hospital prescription sheets especially in the area of Dementia. It does not appear in the BNF (British national formulary)the last time i looked as it is not licensed.What makes that OK i dont know but I will enquire.It seems to work especially in this difficult client group. Benzodiazipines and other sedatives are really useless after a while. If a natural remedy could be used frequently without gradual resistence it would make my job a lot easier and has been suggested here a huge pharmalogical money maker. Frodo

frodo thanks for the info. squidd MA25 looks like its going to cross MA200 all good stuff will it be a strong positive push from there.

On the move up again today.

Up we go yet again they must be really short of stock here and cannot get any decent size sells to its going to have to just keep going up.

MA25 up through MA200 now;

Could well be a bid coming ! I say this as Nigel Wray took up over 3 million of those 19 million buys @15p from Wednesday last week, but we still have not heard anything of the other 16 million and who purchased them on the same day. No news on holdings and we could be looking at a bid here !

DYOR !

squidd all is skyward especially VLK now, Vislink is moving up at quite a rate past few days.

APH going skyward too squidd, strong rise so far this morning on VLK and looking very strong.

Looks like we are hitting some profit taking here.

PpP: Have returned to find bright blue blossom covering APH and my holding now shows a 40% gain since buying only about 6 weeks ago. Would be tempted to add were there any retraction, but bid or no, this one now seems to have a real head of steam and I am looking forward to a profitable ride.
Meanwhile, my own low key enquiries among medics about Melatonin point the same way as that reported by frodo, so here's to Posidorm.
I do like your headers, which I note have spread to others of your favourites and which I continue to monitor.
sd.

squidd it does look good on the APH front. VLK is rumoured to be about to release loads of contract news next week and could be going to 45p or higher. Today UNG gave a good solid trading statement and is one to watch in the coming months for solid gains.

A very nice cross of MA50 through MA200 soon ?

A nice cross of MA50 through MA200 coming ?

squidd terrible news today its so sad !

A Golden Cross is happening and there were some big buys this morning before the sad events.

squidd Hardman June report says 30p is fair value.

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

squidd from the charts lets hope for a solid rise to above 30p.

squidd are you still on holiday ? What do you think of the Hardman write up ? In my opinion Periostat will do better this year than they forecast and Posiderm will be massive for the future.

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

squidd also new presentation on June 22nd 2005 to G.C.I. is available;

http://miranda.hemscott.com/ir/aph/pdf/2005_06_22_growth_company_investor.pdf

what do you think ?

PpP: As a holder of 50k shares in APH, I enjoyed reading the 2 reports. But as a layman, I cannot really comment on the potential of the new products and those under development, other than to agree in general terms about growth prospects.
In any case, I've read too many glowing analysts reports to place to much reliance on them, because at the end of the day, so much depends upon the energy and enterprise of the management team. With APH, I think they know what they are at and are making the right moves, so I'm happy to be on board
(in contrast to ELA, who I felt voiced some muddled thinking at their recent AGM).
But the reports are very positive and help confirm my own views. Additionally, the chart looks to me like a classic recovery, so I'll be looking for an sp of 30p or more by Xmas.
sd.

PpP: I had expected some profit taking here, and it may yet occur, but meanwhile I note what you say about profit taking at VLK. Encouraged by a rise in my TED holding, I will be inclined to add to APH on any dips.
sd.

squidd its very interesting so far that APH remains stable if it can keep this up the next move up will also be quick and strong when it happens. Like you if it drops I will add on the bottom of any drop.

Alliance Pharma PLC
29 July 2005

For Immediate Release 29 July 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')

Leading distributor signed in Turkey for Periostat(R)

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has entered into a distribution agreement with
Vem IIac to register, distribute and market Periostat in Turkey. Simultaneously
to this agreement, Alliance has also extended its agreement with CollaGenex to
add Turkey to its list of available territories.

Periostat is the first and only approved prescription medicine for the treatment of the severe gum disease periodontitis.

Vem IIac, based in Ankara, is a specialist dental pharmaceutical company and is
highly experienced in the dental market in Turkey, where it currently
distributes and sells a range of dental anaesthetics and consumables to more
than 20,000 dental clinics.

Statistics indicate that 22 per cent of the Turkish population has advanced
periodontitis, representing a potential market of approximately nine million
people. Periostat will be the only enzyme suppression product on the market in
Turkey to treat periodontitis.

Alliance and Vem IIac have compiled and submitted the dossier to secure the
marketing authorisation for Periostat in Turkey. This registration process is
expected to take between eighteen months and two years.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:
'I am extremely delighted with these two agreements. Periostat is a major growth opportunity for Alliance Pharma and this agreement with Vem IIac increases our international reach into a well developed dental market that represents a significant commercial opportunity. It has also produced a good understanding between us and CollaGenex on the way forward to exploit markets that were outside our original agreement.'

For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

PpP: APH my No 2 candidate for top-up and after that news, for which thanks, I'd better get in quickly.
On VLK, yours was a timely posting yesterday, and I think I'll just hopefully enjoy the ride from here.
sd.

squidd yes I have topped up in VLK but I am stuck on which one is the next candidate as they are all at times when news, results or trend will move them higher so will have to sit down and think about this over the weekend.

squidd looking at those two big trades yesterday you might be getting some holdings increase news next week so very nicely timed buy if it is.

PpP: You were right about the new holdings. Have noted that Aviva, via their subsidiary Morley, have joined the stake holders, taking up 10% of APH. I'm glad that us ordinary mortals were able to clamber aboard ahead of the action.
sd.

squidd I knew something was going on then and its good news that comes through,will be adding more in the coming months.

PpP: I slept soundly yesterday morning as ULT climbed 50% until wakened by a call from a day trader friend, who urged me to sell. But after we talked about the various scenarios for the global roll out of ULT's CBT and a possible reaction from beleaguered pharmas, defending their tranquilliser pills, he agreed that I would have to buy back pdq, so I'm still in.
I hope that somewhere along the line people will recognise that APH's Posidorm is also a type of traquilliser, but being the body's own produce, is unlikely to have side effects.
sd.

squidd ULT is still up and down but if they can come up with the goods then it should be a lot more up than down in future.

Very interested in BOI at the moment, been slowely adding and I think this will wake up (no Posiderm for BOI to sleep on) very soon. Could give some strong gains through this year and next.

PpP: I sold my APH earlier in the week, at a healthy profit, in order to top up my front runners CSB, AEX and of course ULT. So, very grateful for your hard work on APH which has helped fill my pockets and hoping you are with us on ULT.
sd.

squidd, yes I have taken a small go with ULT and its moving ups so thanks for the nod on ULT. Am taking a closer look at CSB and AEX.

One of my small holdings GRL went up today on very good news, it might have some more go in it too.

Alliance Pharma PLC
11 October 2005
For Immediate Release 11 October 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')
Notification of Interim Results

On behalf of our client Alliance Pharma plc (AIM: APH), the emerging speciality
pharmaceutical company, we notify that they will be reporting their Interims
Results for the six months ended 31 August, on Thursday 3 November, 2005.

For further information:
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.
Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.
Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC
03 November 2005

For Immediate Release 3 November 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')

Uniflu UK disposal raises 500,000

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has divested Uniflu, its cold and flu product,
for a one-off payment of 500,000.

Uniflu was acquired as part of the acquisition of Forceval, a prescription based multi-vitamin for clinical malnutrition, in November 2004. The UK business for Uniflu, as a consumer healthcare product, is non-core to Alliance, therefore the company has taken the decision to divest the brand to G R Lane Health Products Ltd based in Gloucester, UK, for a one-off payment of 500,000. Alliance retains its Uniflu export business, with annual sales of 419,000 which is managed via distributors.

Uniflu's presence in the UK market is underdeveloped compared with its position
in several other markets, particularly Lebanon where it is market leader in the
cold and flu segment.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:

'We have taken the decision to divest Uniflu for a one-off payment as the
product is non-core to the Alliance Pharma business. We continue to retain the
export sales on Uniflu as that market is further developed and offers more value going forward.'

For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Interim Results for the six month period ended 31 Augst 2005

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its interim results for the half year ended 31 August
2005.

Financial Highlights

Sales up 35.5% to 7.5m
Profit after tax, on an IFRS basis was 385K
Gross margin improvement of 53.6%
Operating cashflow remains strong at 1.6m
Basic earnings per share of 0.26p
Financial year changing to December 31st - commencing December 2005

Operational Highlights

Phase III clinical trials on Isprelor(TM), (induction of labour)

- trials expected to complete the middle of 2006

Phase III trials on Posidorm(TM), (melatonin for sleeping disorders),

- on track for introduction in 2007

Selective acquisition of reputable prescription brands under discussion

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said:
'Our interim results for the 6 months to August 2005 represent another period of good, on-target, performance from the current business with solid progress also being made on the development projects. Significant progress has also been made in building and strengthening the managerial team...... We look forward to the next half year with continued optimism.'


Diluted EPS 0.46p

Anyone know why it has fallen 9% today?

Its probably just the December syndrome, end of year, and MM's want to finish the year at evens on as many stocks as they can, so this is why in December on MM controlled stocks, there can be wild price swings up and down as year end positons are cleared and stated.

Alliance Pharma PLC
23 March 2006




FOR IMMEDIATE RELEASE 23 MARCH 2006


ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Preliminary Results for the 10 month period ended 31 December 2005

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce its preliminary results for the ten month period ended 31
December 2005. The results cover a 10 month period owing to a change to the
Company's year end to 31 December 2005, bringing the Company's year end into
line with that of its peers.

Financial Highlights



Sales for the 10 month period of 12.28 million (12 months to 31
December 2004: 11.83m)

Sales growth on an annualised basis of 24.6%

Gross margin improvement to 54.3% (2004: 52.4%)

Operating cashflow remains strong at 1.79 million (2004: 1.57m)

Earnings before interest and tax of 2.17 million (2004: 2.26m)

Pre-tax profit of 0.66 million (2004: 0.41m)

Operational Highlights

Launch of Dental Products division and promotion of Periostat for
periodontitis

Launch of International Division for marketing of Periostat and
Forceval

Start of Phase III clinical trials of Posidorm for sleep disorders

Acquisition of Hydromol dermatology range post the year end

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said: '
During the period under review, Alliance has moved closer to its goal of
delivering substantial and growing revenue streams from brands both acquired and
developed in-house. All our efforts will continue to be directed towards
achieving this goal.'

Recent buying explained, just been tipped today as a long term buy by uk-analyst.com

Alliance Pharma PLC
10 May 2006
ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Placing to raise 2.5 million

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has conditionally placed 14,705,883 new ordinary shares of
1p each in the capital of the Company ('Ordinary Shares') at a price of 17p per
share, raising a total of 2.5 million (before expenses) for the Company.
Application has been made to AIM for the new shares to be admitted to trading,
which is expected to commence on 15 May 2006.

The proceeds of the placing will be used for general corporate purposes.

John Dawson, Alliance Pharma's Chief Executive, commented:

'I am delighted by the support of new and existing investors in this
fundraising, the proceeds of which will provide additional finance as the
Company moves closer to the regulatory filing of key pipeline products including
Posidorm for sleep disorders.'

The placing has been undertaken by Numis Securities Limited ('Numis') and is
conditional on the placing agreement between Numis and the Company becoming
unconditional and not being terminated on or before 15 May 2006 (or such later
date as Numis and the Company may agree, being not later than 30 May 2006). The new Ordinary Shares will rank pari passu in all respects with the existing
Ordinary Shares in issue.

For further information:

Alliance Pharma plc +44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications +44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and international pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC 18 May 2006

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Further expansion of skincare portfolio through bolt-on acquisition
of Caraderm Limited

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has agreed to acquire Caraderm Limited ('Caraderm'), a
Northern Ireland company whose key asset is Dermamist, a dermatological spray
for dry skin conditions.

Based on 2005 volumes, Dermamist will add annualised sales of 108,000 and adds
a further product to Alliance's growing dermatology portfolio.

Alliance is paying 260,000 in cash for the entire share capital of Caraderm,
under a transaction in which staff will not be transferred to Alliance.

John Dawson, Alliance Pharma's Chief Executive, commented: 'This latest
acquisition delivers a further product to our dermatology portfolio. We gained
critical mass in dermatology earlier this year through the acquisition of the
Hydromol range and we look forward to the continuing success of our skincare
franchise.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

PP

Price is heading in wrong direction...any views?

Free research report to read (its free to register and therefore read it) at

http://www.objectivecapital.co.uk/objectiveresearch.asp?


Just Released August 2006.

Not a lot of interest here, anymore. - and the sp seems to be sliding, - not helped by "further research trials" needed by "EuroMedical" or whatever Authority.
I'm not sure about their China connection either; it might be a bold move, or a can of worms - what do others think? (Presently I don't hold and I'd like to know their cash-position, if anyone acan say for certain).
EDIT 29May: Have bought a few as I suspect this is "the bottom" and I like the way Management is open, etc. (so far).

Sudden 25% rise! ( 10.5p mid.)
Looks like I might break-even - - - and today I looked at their products - quite nice range.....

Maybe this signals a takeover, it's a rapid rise for sure.

Proactive Investors One2One Forums

The directors of Netplay TV Plc (AIM: NPT), Synchronica plc (AIM: SYNC) and Alliance Pharma plc (AIM: APH) will be presenting:

Wednesday the 22nd July 2009

Venue : Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.


Register Here : http://www.proactiveinvestors.co.uk/eventregistration.php


These are really good events set in a wonderful location, and are an excellent chance to meet the CEo's of these companies and have an informal chat over free wine and canapafter the formal presentations are complete.

The evenings have a good balance of city professionals, and private investors.

If you have any problems registering or queries please email : action@proactiveinvestors.com


Nearest tube stations are Green Park (5 minutes walk) and Bond Street (7 mins)

Andy,

Did you use to post on the old AOL message board ? if so do you know what as happened to the poster called aknightmight who then changed his name to the french connection and posted on here.

Good news! A Growth equities and Company research report on www.uk-analyst.com talks about APH